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• Early intervention among those with elevated weight status has shown decreased 
risk for cardiometabolic comorbidities1
• Fasting blood glucose (BG), plasma insulin (IN), and blood hemoglobin A1c 
(HbA1c) are common clinical tests to assess diabetic state and insulin resistance
• Previous research has demonstrated that children and adolescents with obesity, 
but who return to normal weight by adulthood have significantly lower risks for 
cardiometabolic diseases, specifically type 2 diabetes mellitus (T2DM)1
• Little research has been performed evaluating young adults’ (YA) risk for insulin 
resistance and T2DM
BACKGROUND
PURPOSE
• Baseline data were analyzed from 460 YA ages 18-35 years enrolled in a healthy 
body weight randomized controlled trial
• Participants underwent clinic-based assessments, which included anthropometric 
measures and fasting (≥ 8 hours) venous and point of care blood samples
• Only individuals who had complete data from fasting blood draws (n=223; 48.5%) 
were included in these analyses 
• HOMA-IR was calculated using the standardized equation: 
!"#$%&' !"#$ ×)*&#"+* %&!$,-.
• Age was dichotomized into younger (18-25 years) and older (26-35 years); race and 
ethnicity were collapsed into one variable, race (white non-Hispanic, non-white 
Hispanic, and unknown/prefer not to answer); BMI was dichotomized into 
overweight (< 30 kg/m2) and obese (≥30 kg/m2)
METHODS
RESULTS
DISCUSSION & CONCLUSIONS
• Our results indicate potential long-term risks for T2DM in this YA population
• In agreement with prior research: increased body mass coincided with higher 
plasma insulin and HOMA-IR score, both measures of insulin resistance3
• In this population, HbA1c was higher in females than in males, which is an 
uncommon finding5
• BG and HbA1c are simple, inexpensive point of care screening tests for pre-
diabetes that could be particularly helpful in preventing diabetes in a YA 
population
• Curtailing the progression of pre-diabetes to diabetes can reduce risk for 
cardiometabolic syndrome and subsequent cardiovascular disease1
• Combining early screening for pre-diabetes with tailored weight-loss and healthy 
eating counselling may decrease incidence of T2DM in YA
• To explore the relationship between IN, BG, and HbA1c in a population at risk for 
insulin resistance and pre-diabetes 
• IN and BG will further be used to generate homeostatic model assessment for 
insulin resistance (HOMA-IR)2,3 scores to model both pancreatic beta cell function 
and insulin sensitivity 
• The following questions will be addressed: 
1. Do YA vary in insulin resistance and pre-diabetes by demographics?
2. Are YA with overweight and obesity at similar risks for diabetes?
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Table 5. Results of t-tests by Sex, Age, and BMI
Outcome Sex
95% CI for Mean Difference
Male Female
M SD n M SD n t df
Blood Glucose 91.27 8.87 48 88.78 8.88 175 -.37, 5.34 1.72 221
HbA1c 5.18 .48 48 5.34 .39 175 -.29, -.03 -2.34* 221
Insulin 12.02 9.74 48 11.89 7.4 175 -2.43, 2.70 .10 221
HOMA-IR 2.78 2.46 48 2.63 1.72 175 -.47, .76 .47 221
Outcome Age
95% CI for Mean DifferenceYounger 
(18-25 years old)
Older
(26-35 years old)
M SD n M SD n t df
Blood Glucose 89.70 9.23 164 88.25 7.95 59 -1.23, 4.11 1.07 221
HbA1c 5.31 .41 164 5.30 .43 59 -.12, .13 .13 221
Insulin 12.25 8.31 164 11.00 6.90 59 -1.13, 3.64 1.04 221
HOMA-IR 2.75 2.00 164 2.41 1.57 59 -.23, .91 1.17 221
Outcome BMI
95% CI for Mean DifferenceOverweight
(<30) Obese(≥30)
M SD n M SD n t df
Blood Glucose 88.74 8.73 116 89.93 9.12 107 -3.54, 1.16 -0.99 221
HbA1c 5.25 .42 116 5.36 .41 107 -2.1, .01 -1.85 221
Insulin 10.11 7.34 116 13.87 8.18 107 -5.81, -1.71 -3.62** 221
HOMA-IR 2.24 1.68 116 3.12 2.02 107 -1.37, -.39 -3.56** 221
* p < .05
**p < .001
Table 3. Analysis of variance (ANOVA) examining BG, HbA1c, IN, and 
HOMA-IR by race
Race
df MS F p
Blood Glucose 2 204.09 2.61 .08
HbA1c 2 1.03 6.22 .00
Insulin 2 78.12 1.23 .29
HOMA-IR 2 3.09 .86 .43
Note: Non-white and unknown/prefer not to answer ppts showed higher HbA1c 
than whites. (White: 5.21; Non-white: 5.40; Unknown: 5.41)
Table 1. Demographic characteristics (n=223)
Age (years) 22.81 (±4.07)
BMI (kg/m2) 31.22 (±4.22)
% Female 78.5
Race/Ethnicity
% Non-white
% White
% Unknown/Prefer not to answer
34.5
52.9
12.6
Plasma Insulin (!U/mL) 11.92 (±7.97)
Blood Glucose (mg/dL) 89.31 (±8.92)
Blood HbA1c (%) 5.30 (±.42)
HOMA-IR 2.66 (±1.9)
Table 4. Prevalence of elevated BG and HbA1c
Glucose HbA1c
Pre-Diabetes Diagnosis
Frequency Percent
WNL WNL 157 70.4
Pre-diabetic WNL 23 10.3
WNL Pre-diabetic 35 15.7
Pre-diabetic Pre-diabetic 7 3.1
WNL Diabetic 1 .4
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Table 2. Reference Ranges
WNL Pre-diabetes Diabetes
Blood Glucose (mg/dL)4 <100 100-125 ≥126
Blood HbA1c (%)4 <5.7 5.7 – 6.4 ≥6.5
Pre-insulin resistant Insulin Resistant
Plasma Insulin (!U/mL)3 < 20 ≥20
HOMA-IR3 ≤ 3.0 3.1-6
Note: Within normal limits (WNL)
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